News Column

Trimel Announces Voting Results for 2014 Annual General and Special Shareholders' Meeting

June 12, 2014



TORONTO, ONTARIO--(Marketwired - June 12, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the voting results from its annual general and special meeting held on June 12, 2014. The total number of shares represented in person or by proxy at the meeting was 121,019,361, representing 74.19% of Trimel's total issued and outstanding shares.

Shareholders voted in favour of the reappointment of the auditors of the company, in favour of ratifying the amended and restated by-laws of the company and voted as follows in connection with the election of the directors of the company: ---------------------------------------------------------------------------- Name Votes For (%) Votes Withheld (%) ---------------------------------------------------------------------------- Ian Ihnatowycz 83,341,992 (69.43%) 36,695,676 (30.57%) ---------------------------------------------------------------------------- John Friedrichsen 120,019,043 (99.99%) 18,625 (0.01%) ---------------------------------------------------------------------------- Stephen Gregory 119,926,872 (99.91%) 110,796 (0.09%) ---------------------------------------------------------------------------- Matthew Pfeffer 83,323,600 (69.41%) 36,714,068 (30.59%) ---------------------------------------------------------------------------- Rolf Reininghaus 119,358,688 (99.43%) 678,980 (0.57%) ---------------------------------------------------------------------------- Tom Rossi 79,224,277 (66.00%) 40,813,391 (34.00%) ---------------------------------------------------------------------------- Jeffrey Sherman 78,541,818 (67.69%) 37,495,850 (32.31%) ---------------------------------------------------------------------------- Dr. D. Lorne Tyrrell 120,006,599 (99.98%) 31,069 (0.02%) ----------------------------------------------------------------------------



For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto(TM), a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.

FOR FURTHER INFORMATION PLEASE CONTACT: Trimel Pharmaceuticals CorporationKenneth G. Howling Chief Financial Officer 416 679 0536 ir@trimelpharmaceuticals.comwww.trimelpharmaceuticals.com Source: Trimel Pharmaceuticals Corporation


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Marketwire (Canada)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters